Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Davis, Zinna Northington (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S148000, C544S159000, C544S406000, C546S316000, C546S323000, C548S333500, C548S537000, C549S438000, C549S487000, C560S010000, C560S013000, C562S427000, C562S430000, C564S085000, C514S090000, C514S117000, C514S351000
Reexamination Certificate
active
08008297
ABSTRACT:
The present invention provides lysine based compounds of the formula;and when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2and R3are as defined herein.
REFERENCES:
patent: 5013861 (1991-05-01), Weller, III et al.
patent: 5527829 (1996-06-01), Kalish
patent: 5614522 (1997-03-01), Talley et al.
patent: 5714605 (1998-02-01), Vazquez et al.
patent: 5776718 (1998-07-01), Palmer et al.
patent: 5965588 (1999-10-01), Vazquez et al.
patent: 5985870 (1999-11-01), Getman et al.
patent: 6022994 (2000-02-01), Vazquez et al.
patent: 6127372 (2000-10-01), Tung et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6384036 (2002-05-01), Freskos et al.
patent: 6436989 (2002-08-01), Hale et al.
patent: 6455587 (2002-09-01), Bouzide et al.
patent: 6506786 (2003-01-01), Stranix et al.
patent: 6528532 (2003-03-01), Stranix et al.
patent: 6656965 (2003-06-01), Stranix et al.
patent: 6608100 (2003-08-01), Stranix et al.
patent: 6610689 (2003-08-01), Stranix et al.
patent: 6632816 (2003-10-01), Stranix et al.
patent: 6677367 (2003-10-01), Stranix et al.
patent: 6703403 (2004-03-01), Norbeck et al.
patent: 7388008 (2008-06-01), Stranix et al.
patent: 2006/0025592 (2006-02-01), Stranix et al.
patent: 2006/0287316 (2006-12-01), Wu et al.
patent: 2009/0253926 (2009-10-01), Milot et al.
patent: 2010/0130765 (2010-05-01), Milot et al.
patent: 2 089 747 (1992-04-01), None
patent: 2 077 948 (1993-03-01), None
patent: 2 316 218 (1999-07-01), None
patent: 2 440 931 (2002-08-01), None
patent: 0532466 (1993-03-01), None
patent: 0 763 017 (1997-03-01), None
patent: 06321950 (1994-11-01), None
patent: 6321950 (1994-11-01), None
patent: WO 92/06998 (1992-04-01), None
patent: WO 95/06998 (1995-03-01), None
patent: WO-95/24385 (1995-09-01), None
patent: WO-97/27180 (1997-07-01), None
patent: WO-98/31664 (1998-07-01), None
patent: WO 99/33815 (1999-07-01), None
patent: WO-99/55687 (1999-11-01), None
patent: WO-00/47551 (2000-08-01), None
patent: WO-00/76961 (2000-12-01), None
patent: WO-01/68593 (2001-09-01), None
patent: WO-02/064551 (2002-08-01), None
patent: WO-03/074467 (2003-09-01), None
patent: WO-2004/054586 (2004-07-01), None
patent: WO-2004/056764 (2004-07-01), None
patent: WO-2005/066131 (2005-07-01), None
patent: WO-2006/012725 (2006-02-01), None
patent: WO-2006/114001 (2006-11-01), None
patent: WO-2007/062526 (2007-06-01), None
Anderson, et al., The use of esters of N-Hydroxysuccinimide in peptide synthesis,J. Am. Chem. Soc., 86:1839-1842 (1964).
Andrade, et al., HIV-related drug metabolism and cytochrome P450 enzymes,AIDS Clin. Care, 12(11):91-95 (2000).
Bouzide, et al., Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies,Bioorg. Med. Chem. Lett.15 (2005) 1509-1513.
Boyle, et al., Asymmetric transformation of α-amino-ε-caprolactam, a lysine precursor,J. Org. Chem., 44(26):4841-4847 (1979).
Bukrinsky, et al., Active nuclear import of human immunodeficiency virus type 1 preintegration complexes,Proc. Natl. Acad. Sci. USA, 89(14):6580-6584 (1992).
Calogeropoulou, et al., Strategies in the design of prodrugs of anti-HIV agents,Current Topics in Medicinal Chemistry, 3(13):1467-1495 (2003).
Chemical Abstracts, 123(7), Abstract 83099w (1995), Harada and Mikio,Jpn. Kokai Tokkyo Koho JP06,321,950, Takeda Chemical Industries, LTD. (1994).
Chemical Abstracts, 46(13), Abstract 6593c (1952), lzumiya,J. Chem. Soc. Japan, Pure Chem. Sect., 72(1):149-152 (1951).
Chemical Abstracts, 46(13), Abstract 6593g (1952), lzumiya,J. Chem. Soc. Japan, Pure Chem. Sect., 72(5):445-447 (1951).
Chemical Abstracts, 46(13), Abstract 6593i (1952), lzumiya,J. Chem. Soc. Japan, Pure Chem. Sect., 72(6):550-552 (1951).
Chemical Abstracts, 62(2), Abstract 1740c (1965), Hermann, et al.,Peptides Proc. European Symp., 5th, Oxford, 171-175 (1962).
Dandache, et al., In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of Human Immunodeficiency Virus Type 1, Antimicrob. Agents Chemother., 51(11):4036-4043 (2007).
Dankwardt, et al., Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-Proteinase. Part 2: Solid-phase optimization of side chains,Bioorg. Med. Chem. Lett.12, 2002, 1233-1235.
El-Naggar, et al., Synthesis and biological activity of some new quinoline-8-sulphonylamino acid and dipeptide derivatives,Acta Pharm. Jugosl., 33(2):103-110 (1983), XP000926585.
El-Naggar, et al., Synthesis of nitrobenzene- and nitrotoluenesulfonylamino acid and dipeptide derivatives,Pol. J. Chem., 52(3):637-642 (1978), XP000926586.
Elmore, et al., Kinetics and mechanism of catalysis by proteolytic enzymes,Biochem. J., 102:728-734 (1967).
Ettmayer, et al., Lessons learned from marketed and investigational prodrugs,Journal of Medicinal Chemistry, 47(10):2393-2404 (2004).
Fitzsimmons, et al., Selective biotransformation of the human immunodeficiency virus protease inhibitor Saquinavir by human small-intestinal Cytochrome P4503A4,Drug Metab. Disp., 25(2):256-266 (1997).
Gallay, et al., HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator,Cell, 80(3):379-388 (1995).
Garrity, et al., A new synthetic route to 2-(p-nitrobenzyI)-1,4,7,10-Tetraazacyclododecane,Tetrahedron Letters, 34(35):5531-5534 (1993).
Goff, Retroviral reverse transcriptase: Synthesis, structure, and function,Journal of Acquired Immune Deficiency Syndromes, 3(8):817-831(1990).
Greene and Wuts, Protection for the amino group,Protective Groups in Organic Synthesis, 3rd Ed., 518-525 (John Wiley & Sons, Inc., 1999).
Greene, Protection for the amino group,Protective Groups in Organic Synthesis, 258-263 (John Wiley & Sons, Inc., 1981).
Hamill, et al., Non-peptide fibrinogen receptor antagonists. Synthesis of [3H]L-756,568,J. Labelled Cpd. Radiopharm., 42(6):605-609 (1999), XP000926587.
Haseltine, Molecular biology of the human immunodeficiency virus type 1,The FASEB Journal, 5(10):2349-2360 (1991).
Hlavacek, et al., An alternative route to Nα-methylamino acid derivatives: Synthesis and conformation of some Nα-acetyl-Nα-methylamino acid methylamides,Collection Czech. Chem. Commun., 53:2473-2494 (1988), XP001002995.
Japour, et al., Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates,Antimicrobial Agents and Chemotherapy, 37(5):1095-1101 (1993).
Karup, et al., 9-acridinylpeptides and 9-acridinyl-4-nitrophenylsulfonylpeptides,Int. J. Peptide Protein Res., 32(5):331-343 (1988), XP000926584.
Kempf, et al., Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with Ritonavir,Antimicrob. Agents Chemother., 41(3):654-660 (1997).
Kolc, Amino acids and peptides,Collect. Czech. Chem. Commun., 34(2):630-634 (1969).
Kottirsch, et al., Beta-amino acid derivatives as orally active non-peptide fibrinogen receptor antagonists,Bioorg. Med. Chem. Lett., 7 (1997) 727-732, XP004136118.
Lasky, et al., Delineation of a region of the human immunodeficiency virus Type 1 gp120 glycoprotein critical for interaction with the CD4 receptor,Cell, 50(6):975-985 (1987).
Leclerc, et al., On the selectivity of acylation of unprotected diamino acids,Can. J. Chem., 46(7):1047-1051 (1968), XP000926722.
Lescrinier, et al., α-Amino acids derived from ornithine as building blocks for peptide synthesis,J. Peptide Res., 49(2):183-189 (1997) , XP000679594.
Maeda, et al., Amino acids and peptides. V. Synthesis of amino acid derivatives containing a sulfonamide bond,Chem. Pharm. Bull., 33(5):2137-2141 (1985), XP001010687.
Matayoshi, et al., Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer,Science, 247(4945):954-958 (1990).
Meek, et al., Inhibition of HIV-1 protease in infected T-Iy
Perron Valerie
Stranix Brent Richard
Ambrilia Biopharma Inc.
Clark & Elbing LLP
Davis Zinna Northington
LandOfFree
Lysine based compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lysine based compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lysine based compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2737699